Announcements Trials

Browse Landscape

Phase

Status

Completed 4 Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 4 Breast 4 Gastrointestinal 3 Classical hematology 2 Other neoplasm 1 Other 1 Myeloid 1 Lymphoid 1 Genitourinary 1 Dermatologic 1 CNS 1

Conditions

Interventions

pembrolizumab 58 Ipilimumab 53 Cyclophosphamide 53 Nivolumab 45 aldesleukin 35 Interleukin-2 26 fludarabine phosphate 22 fludarabine 21 Vemurafenib 20 Temozolomide 19 Radiotherapy 19 dabrafenib 15 trametinib 12 Radiosurgery 11 CTLA-4 Antigen 11 spartalizumab 10 Filgrastim 10 Dacarbazine 10 cobimetinib 9 binimetinib 9 atezolizumab 9 Biopsy 9 poly ICLC 8 Paclitaxel 8 Antilymphocyte Serum 8 encorafenib 7 avelumab 7 Rituximab 7 Introns 7 romidepsin 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Cholecalciferol × Dermatologic × Clear all

NCT01264874 2018-01-31

MelaViD

European Institute of Oncology

Phase 3 Terminated

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡